IP Library Granted Patent US 7,105,150
Granted Patent B2
US 7,105,150 · App. 09/792,098 · Granted Sep 12, 2006

In vivo screening methods using enriched neural stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,105,150
App. No.
09/792,098
Granted
Sep 12, 2006
Kind
B2
Abstract

Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.

Claims (14)

1. A method of drug screening or drug discovery comprising the steps of

a) selecting from a population containing neural or neural-derived cells for cells that bind to monoclonal antibody AC133 or to monoclonal antibody 5E12, thereby producing a population enriched for human neurosphere initiating cells (NS-IC) as compared with the population of neural or neural derived cells,

b) engrafting a non-human mammal with the resulting enriched population;

c) administering a test compound to the non-human mammal; and

d) comparing the effect of administration of said test compound in the engrafted mammal with a control non-human mammal not administered said test compound.

2. The method of claim 1 , wherein said non-human mammal is a rodent.

3. The method of claim 1 , wherein said enriched population is further enriched by selecting and eliminating from the population those cells that bind to monoclonal antibody 8G1 prior to the engrafting of step (b).

4. A method of drug screening or drug discovery comprising the steps of

a) selecting from a population of neural or neural-derived cells for cells that bind to monoclonal antibody AC133, and further enriching said population by additionally selecting for cells that bind monoclonal antibody 5E12, thereby producing a population enriched for human neurosphere initiating cells (NS-IC) as compared with the population of neural or neural derived cells,

b) engrafting a non-human mammal with the resulting enriched population for human CNS-SC which can initiate neurospheres (NS-IC);

c) administering a test compound to the non-human mammal; and

d) comparing the effect of administration of said test compound in the engrafted mammal with a control non-human mammal not administered said test compound.

5. The method of claim 4 , wherein said non-human mammal is a rodent.

6. The method of claim 4 , wherein said enriched population is further enriched by selecting and eliminating from the population those cells that bind to monoclonal antibody 8G1 prior to the engrafting of step (b).

Assignments (4)
SECURITY INTEREST Recorded Apr 22, 2019
From: BOCO SILICON VALLEY, INC.
To: BRIGHT OCEANS INTEL-TELECOM CO., LTD.
Reel/Frame 048958/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2017
From: STEMCELLS CALIFORNIA, INC.; STEMCELLS, INC.
To: BOCO SILICON VALLEY, INC.
Reel/Frame 042665/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2003
From: STEMCELLS, INC.
To: STEMCELLS CALIFORNIA, INC.
Reel/Frame 014137/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2001
From: BUCK, DAVID W.; UCHIDA, NOBUKO; WEISSMAN, IRVING
To: STEMCELLS, INC.
Reel/Frame 011870/0858 →